Inhibition of Meal-Stimulated Gastrin Secretion after Oral Glucose

1976 ◽  
Vol 36 (4) ◽  
pp. 379-381 ◽  
Author(s):  
O. Brandsborg ◽  
M. Brandsborg ◽  
N. A. Lövgreen ◽  
N. J. Christensen
1976 ◽  
Vol 36 (4) ◽  
pp. 379-381 ◽  
Author(s):  
O. Brandsborg ◽  
M. Brandsborg ◽  
N. A. Lövgreen ◽  
N. J. Christensen

1953 ◽  
Vol 25 (4) ◽  
pp. 548-552 ◽  
Author(s):  
Thomas J. Rankin ◽  
Robert L. Jenson ◽  
Mahlon Delp

Ob Gyn News ◽  
2005 ◽  
Vol 40 (8) ◽  
pp. 15
Author(s):  
TIMOTHY F. KIRN

2005 ◽  
Vol 11 ◽  
pp. 28
Author(s):  
Fanny Rodriguez Vallejo ◽  
Juan Manuel Rios Torres ◽  
Francisco J. Gomez-Pérez ◽  
Juan A. Rull Rodrigo ◽  
Bernardo Pérez Enriquez

The Lancet ◽  
1971 ◽  
Vol 298 (7224) ◽  
pp. 605
Author(s):  
D Wingate
Keyword(s):  

1994 ◽  
Vol 72 (03) ◽  
pp. 434-437 ◽  
Author(s):  
E Bruckert ◽  
A Ankri ◽  
P Glral ◽  
G Turpin

SummaryPlasminogen activator inhibitor type-1 (PAI-1) is a key determinant of the fibrinolytic capacity. Its activity correlates with most of the characteristic features of insulin resistance syndrome, i. e. obesity, high blood pressure and hyperlipidemia.We measured plasma PAI-1 antigen levels in 131 asymptomatic men (aged 44.2 ± 11 years) who had been referred for hyperlipidemia. Those taking medication and those with a secondary hyperlipidemia were excluded.We confirmed the correlation between PAI-1 levels and the following variables: body mass index, blood pressure, triglyceride concentration, and blood glucose and insulin levels before and after an oral glucose tolerance test. We also found a significant and independent correlation between PAI-1 and the concentration of the hepatic enzymes glutamyl transferase, alanine aminotransferase and aspartate aminotransferase.Mild liver abnormalities (presumably steatosis) may thus be one of the factors accounting for high plasma PAI-1 levels in hyperlipidemic patients.


Sign in / Sign up

Export Citation Format

Share Document